Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Primary Aldosteronism

Spironolactone vs Eplerenone for Primary Aldosteronism?

At a Glance

Spironolactone is usually first-line for primary aldosteronism because it is effective and affordable, but eplerenone causes fewer hormone-related side effects. Both medicines can raise potassium or affect kidney function, so blood-test monitoring is needed, and their doses are not interchangeable.

Both spironolactone and eplerenone treat primary aldosteronism by blocking the effects of excess aldosterone in your body [1]. When primary aldosteronism affects both adrenal glands (bilateral disease), or when surgery is not an option for unilateral disease, medical therapy with one of these drugs is often the standard of care.

Spironolactone is generally the first-line medical therapy when a medication in this class is indicated. It is highly effective, widely available, and usually less expensive [1]. However, it can cause side effects related to sex hormones, such as breast tenderness or menstrual irregularities. Eplerenone is a more selective alternative that is much less likely to cause these side effects [2]. Eplerenone can be more expensive and may require twice-daily dosing [1].

Warning: Spironolactone and eplerenone are not milligram-for-milligram interchangeable. Never start, stop, or adjust your dose without your clinician’s guidance.

How They Work

Both medications belong to a class of drugs called mineralocorticoid receptor antagonists (MRAs). They work by preventing aldosterone from binding to its receptors. This helps lower your blood pressure and reduces your body’s excretion of potassium, bringing low potassium levels back toward normal [3][4].

When dosed appropriately, both medications are effective [1]. Spironolactone is generally more potent. Some research suggests it may be slightly better at lowering blood pressure and correcting low potassium, though differences are small [2][5]. Because eplerenone is less potent, you may need a higher dose or a twice-daily schedule to achieve the same results [6].

Monitoring Renin

Your doctor will likely monitor a blood test called renin to see if the medication is working. Excess aldosterone suppresses renin, so a rise in your renin levels is a useful biomarker that the medication is adequately blocking the excess aldosterone [1][7]. There is no single universal “target” number; your doctor will interpret your renin based on the specific lab assay used, alongside your blood pressure, potassium, and overall clinical picture.

Side Effect Differences

A key difference between the two medications is their side effect profile, specifically regarding sex hormones.

Spironolactone Side Effects

Spironolactone effectively blocks the aldosterone receptor, but it also binds to androgen receptors (which respond to hormones like testosterone) and stimulates progesterone receptors [3][1]. This can lead to anti-androgen side effects:

  • Breast tenderness or gynecomastia (breast enlargement) in men [2]
  • Menstrual irregularities in women [8]
  • Reduced libido or sexual dysfunction [8]

These side effects can occur at any dose, though the risk generally increases at higher doses and with longer-term use [9].

Eplerenone Side Effects

Eplerenone was designed to be more selective, meaning it primarily targets the aldosterone receptor without interfering as much with sex hormones [3][10]. As a result, it is much less likely to cause gynecomastia or menstrual changes, though sexual symptoms are still possible [11][2]. It is often prescribed as an alternative if a patient experiences bothersome side effects from spironolactone [12].

Shared Risks: Potassium, Kidneys, and Drug Interactions

Because both medications work the same way, they share important risks.

High Potassium (Hyperkalemia)

While these drugs correct low potassium, they can also cause your body to hold onto too much potassium, raising it to dangerously high levels [13]. This risk is higher if you have kidney disease or are older [14]. High potassium often causes no symptoms, but severe cases can lead to severe weakness, palpitations, or fainting—seek urgent medical help if these occur.

You must review all your medications and supplements with your doctor before starting or changing your dose. The risk of high potassium increases significantly if you take:

  • Potassium supplements or potassium-containing salt substitutes (these are often stopped once MRA treatment begins) [4]
  • Blood pressure medications like ACE inhibitors or ARBs [14]
  • NSAID pain relievers (like ibuprofen)
  • Certain antibiotics (like trimethoprim)

Eplerenone also has important interactions with drugs that affect the CYP3A4 liver enzyme, which can change how it is processed in the body. Check with your pharmacist before starting any new prescription or over-the-counter medicine.

Kidney Function Changes

Your kidney function is measured by a blood test called eGFR (estimated glomerular filtration rate). When you start treatment, your eGFR may decline [15]. Excess aldosterone forces the kidneys to filter too quickly (a process called hyperfiltration). MRAs lower the pressure inside the kidneys, returning filtration to a more normal rate, which causes the eGFR number to drop [16][17].

While a modest drop can be an expected hemodynamic change rather than actual kidney damage [18], any significant, rapid, or progressive change requires prompt clinical review to ensure your blood pressure hasn’t dropped too low or that there is no underlying kidney injury [19].

Monitoring Plan

Your doctor should order baseline blood tests to check your potassium and eGFR before you start. These should be rechecked shortly after starting the medication and after any dose change, with ongoing follow-up based on your individual risk factors [14]. Other common side effects to watch for include dizziness, low blood pressure, and increased urination.

Comparison Summary

Feature Spironolactone Eplerenone
Receptor Selectivity Less selective (affects sex hormone receptors) More selective for the aldosterone receptor
Hormone Side Effects Higher risk (gynecomastia, menstrual changes) Much lower risk
Typical Dosing Frequency Often once daily Often twice daily
Potassium & Kidney Risks Requires strict lab monitoring Requires strict lab monitoring
Cost & Availability Usually less expensive, widely available generic Can be more expensive, generic available but varies

Common questions in this guide

What is the main difference between spironolactone and eplerenone for primary aldosteronism?
Both medicines block aldosterone and can lower blood pressure and bring low potassium closer to normal. Spironolactone is usually stronger, less expensive, and often taken once daily, but it is more likely to cause breast or menstrual changes. Eplerenone is more selective and usually causes fewer hormone-related side effects, but it may cost more or require twice-daily dosing.
Which drug is usually started first for primary aldosteronism?
When medication is needed, spironolactone is generally the first choice because it is effective, widely available, and usually less expensive. Eplerenone may be chosen when spironolactone causes bothersome hormone-related effects or when a more selective medicine is preferred. Kidney function, potassium, other medicines, cost, and dosing convenience also matter.
When might medication be used instead of surgery for primary aldosteronism?
These medicines are often used when both adrenal glands produce excess aldosterone or when surgery for one-sided disease is not appropriate. If excess aldosterone comes from one adrenal gland and surgery is safe and suitable, your clinician may discuss an operation as an alternative. The choice requires an evaluation of whether the disease is one-sided or bilateral.
Can I switch between spironolactone and eplerenone at the same dose?
No. Spironolactone and eplerenone are not interchangeable milligram for milligram; eplerenone is less potent and may require a higher dose or twice-daily schedule. A clinician should choose the dose and arrange blood-test monitoring after a switch.
What monitoring is needed after starting either medicine?
Before starting treatment, your clinician should check potassium and eGFR, a blood-test estimate of kidney function. These tests are repeated soon after treatment begins and after dose changes, with ongoing follow-up based on your risk factors. Blood pressure and symptoms are also reviewed during dose adjustment.
Why is renin checked during treatment for primary aldosteronism?
Excess aldosterone usually keeps renin levels low. A rise in renin suggests that the medicine is blocking aldosterone adequately, but there is no single target that applies to everyone. Your clinician interprets renin together with your blood pressure, potassium, and the laboratory test used.
What side effects and drug interactions should I watch for?
Both medicines can cause high potassium and changes in kidney function, often without obvious symptoms. Tell your clinician or pharmacist about potassium supplements or salt substitutes, ACE inhibitors, ARBs, NSAID pain relievers, antibiotics such as trimethoprim, and all other medicines; eplerenone also interacts with some medicines that affect the CYP3A4 liver enzyme. Severe weakness, palpitations, or fainting require urgent medical attention.

Get notified when new evidence is published on hyperaldosteronism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.

    Adler GK, Stowasser M, Correa RR, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(9)):2453-2495 doi:10.1210/clinem/dgaf284.

    PMID: 40658480
  2. 2

    Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis.

    Ho WY, Hsiao CC, Wu PH, et al.

    Therapeutic advances in chronic disease 2024; (15()):20406223241239775 doi:10.1177/20406223241239775.

    PMID: 38511069
  3. 3

    Pharmacological treatment of aldosterone excess.

    Deinum J, Riksen NP, Lenders JW

    Pharmacology & therapeutics 2015; (154()):120-33.

    PMID: 26213109
  4. 4

    Diagnosis and treatment of primary aldosteronism: practical clinical perspectives.

    Young WF

    Journal of internal medicine 2019; (285(2)):126-148 doi:10.1111/joim.12831.

    PMID: 30255616
  5. 5

    A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on Management of Primary Aldosteronism.

    Farah MH, Hegazi M, Firwana M, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(9)):e2833-e2844 doi:10.1210/clinem/dgaf290.

    PMID: 40658500
  6. 6

    SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.

    Pechère-Bertschi A, Herpin D, Lefebvre H

    Annales d'endocrinologie 2016; (77(3)):226-34.

    PMID: 27315759
  7. 7

    Treatment of Primary Aldosteronism.

    Parisien-La Salle S, Hundemer GL, Nehs MA, et al.

    Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26238 doi:10.1161/HYPERTENSIONAHA.126.26238.

    PMID: 41808633
  8. 8

    Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism.

    Tang F, Loh LM, Foo RS, et al.

    Journal of the Endocrine Society 2021; (5(11)):bvab144 doi:10.1210/jendso/bvab144.

    PMID: 34541440
  9. 9

    Efficacy and Safety of Treatment With Low Doses of Spironolactone in Patients With Primary Aldosteronism: A Retrospective Observational Study in a Tertiary Center.

    Sconfienza E, Riancho J, Gebara N, et al.

    Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e24881 doi:10.1161/HYPERTENSIONAHA.125.24881.

    PMID: 41521906
  10. 10

    Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

    Lainscak M, Pelliccia F, Rosano G, et al.

    International journal of cardiology 2015; (200()):25-9.

    PMID: 26404748
  11. 11

    Efficacy and safety of medical treatment of primary aldosteronism: a real-world data study in Spain.

    Goi J, Paja Fano M, Rizo Gellida A, et al.

    European journal of endocrinology 2025; (193(2)):297-309 doi:10.1093/ejendo/lvaf158.

    PMID: 40743244
  12. 12

    Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection.

    Chan CK, Chang YY, Tsai YC, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(10)):1811-1820 doi:10.1016/j.jfma.2021.03.032.

    PMID: 33906783
  13. 13

    Emerging Medical Therapies for Primary Aldosteronism.

    Vibhatavata P, Turcu AF

    Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26229 doi:10.1161/HYPERTENSIONAHA.126.26229.

    PMID: 41685462
  14. 14

    Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.

    Rakugi H, Yamakawa S, Sugimoto K

    Hypertension research : official journal of the Japanese Society of Hypertension 2021; (44(4)):371-385 doi:10.1038/s41440-020-00569-y.

    PMID: 33214722
  15. 15

    Renal damage in primary aldosteronism: a systematic review and meta-analysis.

    Monticone S, Sconfienza E, D'Ascenzo F, et al.

    Journal of hypertension 2020; (38(1)):3-12 doi:10.1097/HJH.0000000000002216.

    PMID: 31385870
  16. 16

    Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism.

    Kobayashi Y, Haze T, Yano Y, et al.

    Kidney international reports 2020; (5(8)):1291-1297 doi:10.1016/j.ekir.2020.06.012.

    PMID: 32775828
  17. 17

    Association Between Plasma Aldosterone Concentration and Intraglomerular Hemodynamics in Primary Aldosteronism.

    Uedono H, Kurajoh M, Toi N, et al.

    American journal of hypertension 2024; (37(10)):801-809 doi:10.1093/ajh/hpae071.

    PMID: 38776410
  18. 18

    Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.

    Wu VC, Chan CK, Chueh JS, et al.

    Journal of the American Heart Association 2023; (12(4)):e028146 doi:10.1161/JAHA.122.028146.

    PMID: 36789834
  19. 19

    Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.

    Nakano Y, Yoshimoto T, Fukuda T, et al.

    Internal medicine (Tokyo, Japan) 2018; (57(17)):2459-2466 doi:10.2169/internalmedicine.0438-17.

    PMID: 29709927

This comparison is for education about medicines used for primary aldosteronism and does not replace medical advice. Do not start, stop, or change either medicine without your clinician's guidance.